Made available in DSpace on 2014-07-29T15:25:18Z (GMT). No. of bitstreams: 1 Tese Marcela Souza Berquo.pdf: 1144728 bytes, checksum: 5ef0c624200c91e9dc3f54dd56320b9a (MD5) Previous issue date: 2012-02-15 / INTRODUCTION: The overactive bladder syndrome (OAB) is a lower urinary tract pathology that negatively affects the quality of life (QOL) of women whose main symptom is your definition for urinary urgency, with or without incontinence usually accompanied by urinary frequency and nocturia in the absence of metabolic, infectious or local. The diagnosis of BH is defined from the clinical symptoms, but the voiding diary and urodynamic studies are good tools for objective evaluation of this pathology. There are several forms of treatment for OAB, are the main pharmacological and physical therapy, physical therapy has been being considered an important option in a clinical setting. OBJECTIVES: to do a systematic review article about physical therapy in the treatment of female miccional urgency, to evaluate and compare the effects, discomfort and improvement in quality of life (QOL) of vaginal electrostimulation and percutaneous tibial nerve stimulation (PTNS) in women with overactive bladder. METHODS: We conducted a comparative, prospective, randomized trial of physiotherapy in the sector of the Hospital Materno Infantil (HMI) in Goiânia-GO, from march 2010 to august 2011. We randomized 40 women with urodynamic diagnosis of detrusor overactivity, mixed incontinence with predominant symptoms of overactive bladder or urinary urgency only in two groups: vaginal electrical stimulation (n=20) and PTNS (n=20), being held 10 sessions in each group. We used urodynamic studies, voiding diary and QoL questionnaire of King's Health Questionnaire (KHQ) before and after the two procedures, and then visual analog scale. Statistical analysis used: Fisher exact tests, chi quadratic, U Mann Whitney and Wilcoxon tests with a significance level of 0.05. RESULTS: In voiding diary was a reduction in urinary frequency, urge incontinence, nocturia and urgency in both groups. The urgency was present in all women and disappeared in 90% in the PTNS group (p<0.001) and 80% in vaginal electrical stimulation (p<0.001). According to urodynamic evaluation, the group of vaginal electrostimulation showed disappearance of detrusor overactivity in 60% (p=0.005) and PTNS in 75% (p= 0.002). The urodynamics showed significant differences in some parameters analyzed within each specific group and to compare the two groups was not observed differences. The scale and the KHQ domains of the two procedures had similar results as physical therapy to improve QOL, but no significant difference between them. In relation to the discomfort of procedures, PTNS in 80% of women reported no discomfort and 80% reported vaginal electrostimulation mild to moderate discomfort (p<0.001). CONCLUSION: There was no significant difference in the effects and QOL between the vaginal electrical stimulation and PTNS. The PTNS promoted less discomfort for women. / INTRODUÇÃO: A síndrome de bexiga hiperativa (BH) é uma patologia do trato urinário inferior que afeta negativamente a qualidade de vida (QV) das mulheres, cujo principal sintoma para a sua definição é a urgência miccional, com ou sem incontinência, geralmente acompanhada por polaciúria e noctúria, na ausência de fatores metabólicos, infecciosos ou locais. O diagnóstico da BH é definido a partir dos sintomas clínicos, porém o estudo urodinâmico e o diário miccional são bons instrumentos de avaliação objetiva dessa patologia. Existem diversas formas de tratamento para a BH, os principais são o farmacológico e a fisioterapia, uma vez que a fisioterapia vem sendo considerada como uma opção de relevância no meio clínico. OBJETIVO: Fazer um artigo de revisão sistemática sobre a atuação da fisioterapia no tratamento da urgência miccional feminina, avaliar e comparar os efeitos, o desconforto e a melhoria na qualidade de vida (QV) da eletroestimulação vaginal e da eletroestimulação transcutânea do nervo tibial posterior (PTNS) em mulheres com bexiga hiperativa. MÉTODOS: Foi realizado um estudo comparativo, prospectivo e randomizado no setor de fisioterapia do Hospital Materno Infantil (HMI) de Goiânia-GO, no período de março 2010 a agosto de 2011. Foram randomizadas 40 mulheres com o diagnóstico urodinâmico de hiperatividade do detrusor, incontinência urinária mista com predomínio dos sintomas de bexiga hiperativa ou apenas urgência miccional em dois grupos: eletroestimulação vaginal (n=20) e PTNS (n=20), sendo realizado 10 sessões em cada grupo. Foram utilizados o estudo urodinâmico, diário miccional e o questionário de QV King s Health Questionnaire (KHQ) antes e após os dois procedimentos, e posteriormente a escala visual analógica. Para análise estatística utilizou-se: os testes Exato de Fisher, Qui Quadrad, u Mann Whitney e Wilcoxon com nível de significância de 0,05. RESULTADOS: No diário miccional houve a redução da frequência miccional, urgeincontinência, noctúria e urgência nos dois grupos. A urgência estava presente em todas as mulheres e desapareceu em 90% no grupo PTNS (p<0,001) e 80% na eletroestimulação vaginal (p<0,001). Conforme avaliação urodinâmica, o grupo da eletroestimulação vaginal apresentou desaparecimento da hiperatividade detrusora em 60% (p=0,005) e na PTNS 75% (p=0,002). A urodinâmica demonstrou diferença significante em alguns parâmetros analisados dentro de cada grupo específico e ao comparar os dois grupos não foi constatado diferenças. Quanto à escala e os domínios do KHQ os dois procedimentos da fisioterapia apresentaram resultados similares quanto à melhora da QV, mas sem diferença significativa entre eles. Em relação ao desconforto dos procedimentos, na PTNS 80% das mulheres relataram ausência de desconforto e na eletroestimulação vaginal 80% relataram desconforto leve a moderado (p<0,001). CONCLUSÃO: não houve diferença significativa nos efeitos e na QV entre a eletroestimulação vaginal e a PTNS. A PTNS promoveu menos desconforto para as mulheres.

This thesis concerns the investigation of novel immunotherapies for cancer eradication. CpG therapy was used in order to target antigen-presenting cells (APCs), facilitating antigen presentation and activation of T cells. Blockade of the two major immune checkpoint regulators (CTLA-4 and PD-1) was also studied to ensure proper and sustained T cell activation. The therapies were investigated alone and compared to BCG, the standard immunotherapy in the clinic today for bladder cancer. In addition, CpG as well as BCG was combined with CTLA-4 or PD-1 blockade to examine if the combination could improve therapy. Single and combination strategies were assessed in an experimental bladder cancer model. In addition, one of the therapies (local aCTLA-4 administration) was evaluated in an experimental pancreatic cancer model. To be able to study the effects of CpG in humans, a human whole blood loop system has been used. This allowed us to dissect the potential interplay between CpG and complement. CpG was found to be superior to the conventional therapy, BCG, in our experimental model and T cells were required in order for effective therapy to occur. Used as a monotherapy, CTLA-4 blockade but not PD-1 blockade, prolonged survival of mice. When CTLA-4 or PD-1 blockade was combined with CpG, survival was enhanced and elevated levels of activated T cells were found in treated mice. In addition, Treg levels were decreased in the tumor area compared to tumors in control treated mice. CTLA-4 blockade was also effective when administrated locally, in proximity to the tumor. Compared to systemic CTLA-4 blockade, local administration gave less adverse events and sustained therapeutic success. When CpG was investigated in a human whole blood loop system it was found to tightly interact with complement proteins. This is an interesting finding which warrants further investigation into the role of TLRs in complement biology. Tumor therapy could be affected either negatively or positively by this interaction. The results presented herein are a foundation for incorporating these combination therapies into the clinic, specifically for bladder cancer but in a broader perspective, also for other solid tumors such as pancreatic cancer.

Copy number variation (CNV) comprises a recently discovered kind of variation involving deletion and duplication of DNA segments of variable size, ranging from a few hundred basepairs to several million. By altering gene dosage levels or disrupting proximal or distant regulatory elements CNVs create human diversity. They represent also an important factor in human evolution and play a role in many disorders including cancer. Array-based comparative genomic hybridization as well as expression arrays are powerful and suitable methods for determination of copy number variations or gene expression changes in the human genome. In paper I we established a 32K clone-based genomic array, covering 99% of the current assembly of the human genome with high resolution and applied it in the profiling of 71 healthy individuals from three ethnic groups. Novel and previously reported CNVs, involving ~3.5% of the genome, were identified. Interestingly, 87% of the detected CNV regions overlapped with known genes indicating that they probably have phenotypic consequences. In papers II through IV we applied this platform to different tumor types, namely two collections of brain tumors, glioblastoma (paper II) and medulloblastoma (paper III), and a set of bladder carcinoma (paper IV) to identify chromosomal alterations at the level of DNA copy number that could be related to tumor initiation/progression. Tumors of the central nervous system represent a heterogeneous group of both benign and malignant neoplasms that affect both children and adults. Glioblastoma and medulloblastoma are two malignant forms. Glioblastoma often affects adults while the embryonal tumor medulloblastoma is the most common malignant brain tumor among children. The detailed profiling of 78 glioblastomas, allowed us to identify a complex pattern of aberrations including frequent and high copy number amplicons (detected in 79% of samples) as well as a number of homozygously deleted loci. These regions encompassed not only previously reported oncogenes and tumor suppressor genes but also numerous novel genes. In paper III, a subset of 26 medulloblastomas was analyzed using the same genomic array. We observed that alterations involving chromosome 17, especially isochromosome 17q, were the most common genomic aberrations in this tumor type, but copy number alterations involving other chromosomes: 1, 7 and 8 were also frequent. Focal amplifications, on chromosome 1 and 3, not previously described, were also detected. These loci may encompass novel genes involved in medulloblastoma development. In paper IV we examined for the presence of DNA copy number alterations and their effect on gene expression in a subset of 21 well-characterized Ta bladder carcinomas, selected for the presence or absence of recurrences. We identified a number of novel genes as well as a significant association between amplifications and high-grade and recurrent tumors which might be clinically useful. The results derived from these studies increase our understanding of the genetic alterations leading to the development of these tumor forms and point out candidate genes that may be used in future as targets for new diagnostic and therapeutic strategies.

La present tesi avalua les diferències entre homes i dones quant a les característiques sociodemogràfiques i clínicopatològiques, procés diagnòstic, tractament i pronòstic en una sèrie de casos diagnosticats de novo de càncer de bufeta en 18 hospitals de 5 regions espanyoles (estudi EPICURO). També s'estudia l'associació entre tabac i risc de càncer de bufeta segons el sexe en un estudi agregat d'estudis cas-control europeus i nord-americans de càncer de bufeta.Es trobaren diferències entre sexes quant a la incidència de la malaltia, en algunes característiques anatomopatològiques dels tumors i quant a tractament. No es varen observar diferències entre sexes davant d'un mateix nivell d'exposició al tabac. També s'observaren diferències entre homes i dones quant al risc de recidivar i de progressar dels tumors vesicals superficials, però no en el risc de morir dels pacients amb tumors invasius. / The thesis evaluates differences related to sociodemographic and clinic-pathological characteristics, diagnostic tests, treatment and prognosis of bladder cancer patients newly diagnosed in 18 hospitals from 5 Spanish areas according to sex. The work also assess the association between tobacco and bladder cancer risk according to sex in a pooled analysis of case-control studies of bladder cancer from Europe and North America.Differences between sex concerning disease incidence, pathological characteristics and treatment were observed. The relative risk of bladder cancer associated with tobacco was similar in both sex. Differences between men and women were observed regarding risk of recurrence and progression of their superficial tumors but not regarding risk of death because of an invasive tumor.

L'objectiu d'aquest tesi és avaluar els diferents passos en el camí que va des de l'exposició a contaminants atmosfèrics/PAHs fins a la malaltia, el càncer de bufeta urinària. Es van mesurar partícules ultrafines a Barcelona. S'ha avaluat l'exposició a contaminació atmosfèrica en un estudi cas-control, recollint informació sobre la història residencial incloent diversos indicadors de l'exposició a contaminació atmosfèrica i altres factors de risc potencials. Es va dur a terme una revisió sistemàtica de la literatura per avaluar si els nivells de metabòlits del pirè i els aductes d'ADN i de proteïnes es correlacionaven amb nivells baixos d'exposició a PAHs. Vam mesurar els nivells d'aductes d'ADN en un subgrup d'individus de l'estudi cas-control amb la tècnica del radioetiquetatge amb fòsfor-32, tractament de la nucleasa P1. Vam analitzar 22 SNPs en set gens de la via de reparació de l'ADN per excisió de nucleòtids. / The aim of this thesis is to evaluate the different steps in the pathway from exposure (air-contaminants/PAHs) to disease (bladder cancer). We measured ultrafine particles in Barcelona. We evaluated the exposure to air pollutants in a case-control study, collecting information on the residential history with proxies for exposure to air pollution and other potential risk factors. We did a systematic review of the literature to evaluate if pyrene metabolites and DNA and protein adducts are correlated with low level exposure to PAHs. We measured bulky DNA adducts in a subgroup of subjects of the case-control study using 32P-Postlabeling, nuclease P1 treatment. We analyzed 22 SNPs in 7 genes of the nucleotide excision repair pathway.

Paclitaxel is one of the most successful drugs for the treatment of cancer because of its ability to target tubulin, block cell cycle progression at mitosis, and induce apoptosis. Despite the success of Paclitaxel, the development of drug resistance hampers its clinical applicability. Paclitaxel is used in malignant tumors in the present research, including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), head-neck scale epitheliomatous, urinary bladder cancer, tumor of the reproduction organ and so on. Clinical treatment of paclitaxel be injected 250mg/m2 to previously non-treated patients of small lung cancer its effect about 34% and previously non-treated patients of non-small lung cancer its effect about 21% to 24% . On the other hand we had established a taxol-resistant human lung carcinoma subline A549R by paclitaxel to compare the different proteins with A549 wild type and treat the different concention of paclitaxel with MTT assay so as to observe the tolerance dosage of subline growth.We obtained the patient¡¦s specimens of lung cancer to treat with paclitaxel some of resistant and some of non-resistant to compare differentially expressed proteins between normal and tumor. When we cultured taxol-resistant human lung carcinoma subline in which paclitaxel and calcium regulate growth, owing to the proteins of changes result to resistance. The extraction cell subline and specimens were analyzed by 2-D electrophoresis patterns and we found that interact paclitaxel with calcium it is the important factor of drug resistant. Verified from clinical treatment might have hypercalcemia in malignant tumors and calcium ion may increase paclitaxel drug resistance and hypercalcemia patient will be more insensitive to paclitaxel treatment.

Tyrimo tikslas: išsiaiškinti slaugytojų vaidmenį su šlapimo pūslės kateterizacija susijusių šlapimo takų infekcijų išsivystyme ir profilaktikoje. Tyrimo uždaviniai: 1. Įvertinti slaugytojų, dirbančių reanimacijos ir intensyvios terapijos skyriuose, teorines žinias apie šlapimo takų infekcijas, jų rizikos veiksnius bei profilaktiką; 2. Įvertinti ar slaugytojos, dirbančios reanimacijos ir intensyvios terapijos skyriuose, žino kaip taisyklingai atlikti šlapimo pūslės kateterizaciją laikantis slaugos procedūrų metodikos reikalavimų; 3. Nustatyti, kokias profilaktikos priemones bei metodus taiko reanimacijos ir intensyvios terapijos skyrių slaugytojos, kad būtų išvengta šlapimo takų infekcijų; 4. Pateikti praktines rekomendacijas. Tiriamoji grupė: tyrime dalyvavo 104 slaugytojos, dirbančios KMUK, Kauno 2-osios klinikinės ligoninės, Kauno apskrities ligoninės ir Kauno Raudonojo Kryžiaus klinikinės ligoninės reanimacijos ir intensyvios terapijos skyriuose. Tyrimo metodai: anketinė apklausa ir statistinė duomenų analizė. Tyrimas buvo atliekamas 2009 m. vasario – kovo mėnesiais. Apklausai naudota nestandartizuota autorinė anketa, kuri buvo sudaryta remiantis literatūros analize ir Lietuvos Respublikos sveikatos apsaugos ministro įsakymu patvirtinta higienos norma HN 47-1:2008 “Sveikatos priežiūros įstaigos. Higieninės ir epidemiologinės priežiūros reikalavimai.“, ir tyrėjos paruoštas veiklos testas. Tyrimo metu gauti duomenys apdoroti naudojant SPSS 13.0 versijos statistinį duomenų... [toliau žr. visą tekstą] / The goal of the research – to find out what is the role of the nurses in the development and prophylaxis of the catheter – associated urinary tract infections. Research tasks: 1. Evaluate the theoretical knowledge about the urinary tract infections and their risk’s factors and prophylaxis of the nurses working in the units of Intensive care; 2. Evaluate do the nurses working in the units of Intensive care know how to do the urinary bladder catheterization properly according to the requirements of the methodology of the care procedures; 3. Estimate what preventive measures and methods are used by the nurses of Intensive care units in order to avoid the urinary tract infections; 4. Give the practical recommendations. Investigative group: 104 nurses working in the units of intensive care in Kaunas University Hospital, the Second Kaunas Clinical Hospital, Kaunas Regional Hospital and Kaunas Red Cross Hospital took part in this research. The methods of the research: questionnaire and statistical data analyses. The research was made from January to March in the year 2009. The nonstandard authorized questionnaire which was made according to the analyses of the literature and certified hygiene norm HN 47-1:2008 „Health Care Institutions. Sanitary and epidemiological care requirements.“ affirmed by the Minister of Health of the Republic of Lithuania and the test prepared by the researcher. The data received during the research chiseled using the SPSS 13.0 version of the... [to full text]

During recent years, significant advances have been made in the field of molecular therapy in urologic oncology, mainly for advanced renal cell carcinoma. In this hitherto largely treatment-refractory disease, several agents have been developed targeting the von Hippel-Lindau metabolic pathway which is involved in carcinogenesis and progression of the majority of renal cell carcinomas. Although cure may not be expected, new drugs, such as the multikinase inhibitors sorafenib and sunitinib and the mammalian target of rapamycine inhibitor temsirolimus, frequently stabilize the disease course and may improve survival. Fewer data are available supporting molecular therapies in prostate, bladder, and testicular cancers. Preliminary data suggest a potential role of high-dose calcitriol and thalidomide in hormone-refractory prostate cancer, whereas targeted therapies in bladder and testicular cancers are still more or less limited to single-case experiences. The great theoretical potential and the multitude of possible targets and drug combinations, however, support further research into this exciting field of medical treatment of urologic malignancies. / Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.

Ο καρκίνος της ουροδόχου κύστης είναι η τέταρτη συχνότερη κακοήθεια στους άνδρες και η δέκατη στις γυναίκες και η ετήσια επίπτωσή του αυξάνει συνεχώς στις ανεπτυγμένες χώρες. Oι προγνωστικοί παράγοντες που χρησιμοποιούνται σήμερα δεν μπορούν να προβλέψουν με βεβαιότητα την μακροπρόθεσμη έκβαση του ουροθηλιακού καρκίνου και έτσι προκύπτει η ανάγκη αναγνώρισης δεικτών με δυνατότητα πρόγνωσης της συμπεριφοράς των καρκινωμάτων. Επιπλέον, δεδομένων των περιορισμένων δυνατοτήτων των σημερινών θεραπευτικών επιλογών (χειρουργική αντιμετώπιση, χημειοθεραπεία ή ανοσοθεραπεία και ακτινοθεραπεία), απαιτούνται νέες θεραπευτικές στρατηγικές. Μία τέτοια στρατηγική είναι η στόχευση σε μεταγραφικούς παράγοντες όπως οι πυρηνικοί υποδοχείς και οι upstream ενεργοποιητές τους. Η διαταραχή αυτών των μεταγραφικών παραγόντων είναι κομβικό σημείο της έναρξης και διατήρησης του κακοήθους φαινοτύπου. O πυρηνικός υποδοχέας PPARγ εμπλέκεται στον έλεγχο του μεταβολισμού, την κυτταρική ανάπτυξη, την αγγειογένεση και την ανοσολογική και φλεγμονώδη απάντηση. Επιπρόσθετα, υπάρχουν ενδείξεις ότι ρυθμίζει τους μηχανισμούς καταστολής αλλά και προαγωγής της καρκινογένεσης. Ο RXRα είναι επίσης μέλος της υπεροικογένειας των πυρηνικών υποδοχέων και ετεροδιμερίζεται με τον PPARγ προς σχηματισμό του συμπλόκου που αλληλεπιδρά με το DNA. Οι προσδέτες των RXR υποδοχέων έχουν ήδη χρησιμοποιηθεί στη χημειοπρόληψη διαφόρων μορφών καρκίνου. Ο μεταγραφικός παράγoντας AP-1, απαρτίζεται από διμερή των Fos και Jun πρωτεϊνών και η δράση του σχετίζεται με την πρόοδο της καρκινογένεσης. Υπάρχουν πάντως και ενδείξεις για προ-αποπτωτική δράση του. Η CBP είναι ένας απ’ τους σημαντικότερους ολοκληρωτές σημάτων της μεταγραφής. Ο ανταγωνισμός μεταξύ των PPARγ και AP-1 για τη CBP είναι ένας απ’ τους μηχανισμούς που εξηγούν την αρνητική «συνομιλία» (cross-talk) μεταξύ των PPARγ και AP-1. Στην παρούσα μελέτη εξετάσαμε τόσο ξεχωριστά όσο και σε συνδυασμό μεταξύ τους, την έκφραση των πέντε μοριακών παραγόντων (PPARγ, RXRα, p-c-Jun, c-Fos, CBP) στο φυσιολογικό ουροθήλιο, τις προκαρκινικές αλλοιώσεις και τα ουροθηλιακά καρκινώματα (ΟΚ). Τα ιστικά δείγματα προήλθαν από 88 ασθενείς οι οποίοι υπέστησαν διαγνωστική βιοψία ή θεραπευτική κυστεκτομή, νεφρεκτομή ή ουρητηρεκτομή. Εφαρμόστηκε η ανοσοϊστοχημική μέθοδος σε τομές παραφίνης και εκτιμήθηκε η σχετική έκφραση των μελετώμενων παραγόντων στα ενδοκυττάρια διαμερίσματα, τις ενδοεπιθηλιακές στιβάδες και τις φυσιολογικές ή παθολογικές ιστολογικές βαθμίδες. Όλοι οι παράγοντες παρουσίασαν κυρίως πυρηνική εντόπιση. Η έκφραση του p-c-Jun ελαττώνεται στους ασθενείς άνω των 70 ετών σε σχέση με τους νεώτερους, ενώ κανένα άλλο απ’ τα μελετώμενα μόρια δε φαίνεται να επηρεάζεται από την ηλικία. Η έκφραση των PPARγ, CBP, p-c-Jun και c-Fos σημειώνει αύξηση κατά την πορεία προς τον καρκίνο. Όσο αφορά στα ΟΚ, οι PPARγ και CBP παρουσιάζουν αρνητική συσχέτιση με την αποδιαφοροποίηση. Επιπλέον ο PPARγ συσχετίζεται αρνητικά με την απόκτηση χαρακτήρων διήθησης στα ΟΚ. Αντιθέτως, η έκφραση του RXRα δεν διακυμαίνεται στατιστικώς σημαντικά σε όλη την πορεία της καρκινογένεσης. Η ανάλυση της συνδυασμένης έκφρασης των πέντε παραγόντων έγινε με σκοπό την αποκάλυψη ενδεχόμενων αλληλεπιδράσεων μεταξύ τους. Η προστατευτική δράση του PPARγ στο ουροθήλιο συνοδεύεται από ταυτόχρονη μέτρια ή ισχυρή έκφραση των RXRα, p-c-Jun και c-Fos. Αναλυτικά, η αυξανόμενη έκφραση του p-c-Jun συμπίπτει με ενίσχυση της θετικής συσχέτισης του PPARγ με καλύτερα διαφοροποιημένους, λιγότερο διηθητικούς όγκους, ενώ ο c-Fos φαίνεται να εξασθενίζει ήπια την ευνοϊκή δράση του PPARγ στη διαφοροποίηση του ουροθηλίου. Η αυξανόμενη έκφραση της CBP έδειξε να εξασθενίζει και τελικά να εκμηδενίζει τη στατιστικά σημαντική αύξηση του PPARγ στην πορεία προς τον καρκίνο και την επαγωγή του στους μη διηθητικούς όγκους σε σύγκριση με τους διηθητικούς. Ταυτόχρονα, η αρνητική σχέση της CBP με την αποδιαφοροποίηση και την αύξηση της κακοήθειας των ΟΚ επηρεάζεται από την παρουσία των PPARγ και AP-1, επιβεβαιώνοντας την υπόθεση της συνομιλίας αυτών των μοριακών παραγόντων. Ενδιαφέρουσα είναι η παρατήρηση ότι οι περισσότερες από τις αναφερθείσες πιο πάνω συσχτίσεις μεταξύ των μοριακών παραγόντων ίσχυαν για μεγαλύτερους των 70 ετών αλλά όχι πάντα για τους νεώτερους ασθενείς. Τα αποτελέσματα της παρούσας μελέτης μπορούν πιθανόν να οδηγήσουν σε συμπεράσματα με εφαρμογή σε χημειοπροληπτικές και θεραπευτικές στρατηγικές για τον ουροθηλιακό καρκίνο. / Bladder cancer is the fourth and tenth most common malignancy in men and women, respectively, and its incidence is increasing annually in the developed countries. Current prognostic parameters cannot predict with certainty the long-term outcome of bladder cancer and as a result there is a need to identify markers that may predict tumor behavior. Furthermore, given the limitations of current therapeutic options (surgery, chemotherapy or immunotherapy and radiotherapy), novel treatment strategies are very much needed. One such strategy targets transcription factors such as nuclear receptors and their upstream activators. Disruption of these transcription factors is a key element in the initiation and maintenance of a malignant phenotype. The nuclear receptor PPARγ is involved in controlling metabolism, cell growth, angiogenesis, and immune and inflammatory responses. In addition, it has also been suggested that it regulates tumor suppression as well as tumor promotion. RXRα is another member of the nuclear receptor superfamily, that partners PPARγ to form the DNA-binding complex. RXR ligands are already being used as chemopreventive agents in various types of cancer. The transcription factor AP-1 is formed by dimerization of Jun and Fos proteins and its activity is often associated with tumor progression. On the other hand, there is also evidence that AP-1 may enhance apoptosis. CBP is one of the most important transcriptional integrators. The competition of PPARγ and AP-1 for CBP is one of the multiple mechanisms that explain the negative PPARγ/AP-1 cross-talk. In the present study, we assessed separate and concurrent expression of the five factors (PPARγ, RXRα, p-c-Jun, c-Fos, CBP) in normal urothelium, precancerous lesions and urothelial carcinomas (UC). Clinical samples were derived from 88 patients who had undergone diagnostic biopsy or therapeutic excision of the bladder, the kidney or the ureter. Parafin section immunohistochemistry was utilized and relative expression was estimated in intracellular compartments, intraepithelial layers and histologic categories of urothelium. All five factors had mainly nuclear pattern of expression. P-c-jun was downregulated in patients older than 70 years old compared to younger ones, whereas age did not affect the expression of the rest four factors. PPARγ, CBP, p-c-Jun and c-Fos were upregulated towards tumorigenesis. PPARγ and CBP showed an inverse relationship with carcinoma level of differentiation. Moreover, PPARγ expression downregulated significantly in invasive tumors compared to non-invasive ones. On the contrary, RXRα expression did not vary significantly along the carcinogenesis course. The following correlations were based on coexpression analysis to reveal molecular interactions between the five factors. The established protective effect of PPARγ on urothelium was accompanied by concomitant RXRα, p-c-Jun and c-Fos moderate or strong expression. In detail, p-c-Jun’s increasing expression strengthened the positive relation of PPARγ with better differentiated, less invasive tumors, whereas c-Fos seemed to mildly lessen PPARγ’s favourable effect in urothelium differentiation. Statistically significant PPARγ upregulation in malignant tissues compared to normal urothelium and in non-invasive tumors compared to invasive ones is suppressed and finally cancelled by CBP’s increasing expression. PPARγ and AP-1 seemed to influence the negative relation of CBP with loss of differentiation and increase of malignant potential in UC, an observation that denotes a cross-talk between these molecular factors. Interestingly, most of the aforementioned correlations were noticed in patients older than 70 years old, but not all of them were plausible in younger patients. The results from the present study could lead to conclusions possibly applicable in chemoprevention and therapy strategies for urothelial carcinomas.

Base teórica: Disfunções do trato urinário inferior são sintomas não motores comuns na Doença de Parkinson (DP) e incluem a Síndrome da Bexiga Hiperativa Neurogênica (SBHN), caracterizada pela urgência miccional, com ou sem urgeincontinência, acompanhada de aumento da frequência urinária e noctúria. A estimulação do nervo tibial posterior (ENTP) é uma das modalidades de tratamento disponíveis para o tratamento da SBHN. Objetivo: Determinar e comparar os efeitos do tratamento com ENTP em pacientes com DP e sintomas de SBHN e a manutenção dos resultados em 1 e 3 meses após o término do tratamento. Métodos: Ensaio-clínico, duplo-cego, randomizado, controlado e comparado com placebo. A pesquisa foi realizada com mulheres com DP e sintomas de SBHN no Hospital de Clínicas de Porto Alegre. Para o tratamento com ENTP domiciliar por 12 semanas as pacientes foram divididas em dois grupos: grupo ENTP e grupo ENTP sham/placebo. A avaliação da resposta pré e pós-tratamento foi realizada através de formulário específico, questionários de avaliação da incontinência urinária e qualidade de vida (OAB-V8 e KHQ) e de um diário miccional (DM) de 24 horas. Após, o fim do tratamento foi feito seguimento dos resultados para avaliação da melhora subjetiva em 30 e 90 dias. Resultados: O grupo ENTP apresentou uma diminuição da noctúria, número de episódios de urgência micciional e urge-incontinência, número de uso de proteções para incontinência, pontuação OAB-V8 e em sete domínios do KHQ (p <0,001). Embora, o grupo controle também tenha apresentado melhora dos sintomas, o grupo ENTP apresentou uma melhora superior no final do tratamento nas medidas do DM, OAB-V8 e na maioria dos domínios do KHQ. A ETNTP foi considerada um tratamento efetivo para SBHN em 93,3%, enquanto 33,3% dos tratados com placebo também melhoraram (p = 0,002). No seguimento de 30 e 90 dias, 53,3% e 33,31%, respectivamente, do grupo ENTP relataram que mantinham- se melhores dos sintomas da SBHN. Conclusão: a ENTP foi um tratamento efetivo para as pacientes com DP e SBHN. Nossa hipótese de superioridade clínica do grupo ENTP foi confirmada e a melhora subjetiva foi considerada positiva, mesmo que parcialmente em 30 e 90 dias após fim do tratamento. / Blackround: Lower urinary tract dysfunctions are common non-motor symptoms in Parkinson's disease (PD) and include Neurogenic Overactive Bladder Syndrome (NOBS), characterized by urinary urgency, with or without urge incontinence, accompanied by increased urinary frequency and nocturia . Posterior Tibial Nerve Stimulation (PTNS) is one of the treatment modalities available for the treatment of NOBS. Objective: To determine and compare the effects of PTNS treatment in patients with PD and NOBS symptoms and to maintain long-term results (1 and 3 months). Methods: Controlled, randomized, double-blind and compared with placebo clinical trial. The research was carried out with women with PD and symptoms of NOBS at the Hospital de Clínicas de Porto Alegre. For treatment with PTNS at 12 weeks, patients were divided into two groups: PTNS group and PTNS sham/placebo group. The evaluation of the pre- and post-treatment response was through a specific form, questionnaires to evaluate incontinence and quality of life (OVA-V8 and KHQ), and a voiding diary. After the end of the treatment, the results were followed up to evaluate the subjective improvement in 30 and 90 days. Results: The PTNS group presented a decreased nighttime urinary frequency, number of urgency and urinary incontinence episodes, number of incontinence protection, OAB-V8 and 7 domains of KHQ (p<0.001). Although the control group also showed improvement of the symptoms, the ENTP group presented a superior improvement at the end of the treatment in DM, OAB-V8 and most KHQ domains. PTNS was considered an effective treatment for OAB in 93.3%, while 33.3% of those treated with placebo was considered a responder (p=0.002). After 30 and 90 days, 53.3% and 33.31%, respectively, of the ENTP group reported that they maintained better SBHN symptoms. Conclusion: PTNS was an effective treatment for patients with PD and NOBS. Our hypothesis of clinical superiority of the ENTP group was confirmed and the subjective improvement was considered positive, even if partially at 30 and 90 days after the end of the treatment.!